10 Oct, EOD - Indian

Nifty IT 35609.05 (-0.05)

Nifty Next 50 68687.25 (0.24)

Nifty Bank 56609.75 (0.74)

Nifty Smallcap 100 18133.35 (0.74)

Nifty Midcap 100 58697.4 (0.46)

Nifty Pharma 22218.25 (1.29)

Nifty 50 25285.35 (0.41)

SENSEX 82500.82 (0.40)

10 Oct, EOD - Global

NIKKEI 225 48088.8 (-1.01)

HANG SENG 26290.32 (-1.73)

S&P 6607.25 (-2.71)


Stock Alert News

You are Here : Home > News > Stock Alert News >

(16 Jul 2025, 08:03)

Stock Alert: ICICI Lombard, HDB Financial, HDFC Life, Zydus Lifesciences


Securities in F&O Ban:

Glenmark Pharmaceuticals, Hindustan Copper and RBL Bank shares banned from F&O Trading on 16 July 2025.

Upcoming Results:

Tech Mahindra, ITC Hotels, Angel One, D B Corp, Le Travenues Tech, Kalpataru, and L&T Technology Services will declare their results later today.

Stocks to Watch:

ICICI Lombard General Insurance Company reported a 28.7% jump in standalone net profit 747.08 crore on 14.3% increase in total income to Rs 6,408.54 crore in Q1 FY26 over Q1 FY25.

HDFC Life Insurance Company’s standalone net profit jumped 14.4% to Rs 546.46 crore on 9.5% increase in total income to Rs 29,521.77 crore in Q1 FY26 over Q1 FY25.

Just Dial’s consolidated net profit climbed 38.4% to Rs 115.74 crore on 16.2% jump in net sales to Rs 270.27 crore in Q1 June 2025 over Q1 June 2024.

Arisinfra Solutions has signed memorandum of undertaking (MoU) with Wadhwa Construction and Infrastructure, to supply materials for a development of 7 new towers totalling to a 1.2 million sq. ft. of construction area. This extension is expected to contribute an additional Rs 75 crore to Arisinfra’s material supplies over the next 36 to 40 months.

HDB Financial Services’ consolidated net profit declined 19.1% to Rs 530.90 crore despite a 16.3% increase in total income to Rs 4,266.10 crore in Q1 FY26 compared with Q1 FY25.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID).

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +